OBJECTIVES: To analyze whether the antioxidant melatonin could reduce the hyperoxidative status in the blood of patients with Duchenne's muscular dystrophy. DESIGN AND METHODS: Ten patients aged 12.8±0.9 years were treated with melatonin (60mg at 21:00h plus 10mg at 09:00h) for 9 months, and erythrocyte markers of oxidative stress were determined at 3, 6, and 9 months of treatment. Healthy age- and sex-matched subjects served as controls. RESULTS: Prior to treatment, the patients had higher glutathione disulfide/glutathione ratio and higher glutathione transferase and superoxide dismutase activities, and lower glutathione reductase activity than controls. After 3 months of melatonin treatment, the hyperoxidative status of these patients was counteracted, being reduced to the normal redox state between 3 and 9 months. CONCLUSION: These results, together with the reduction in the inflammatory process and in muscle injury recently reported in the same patients, support the efficacy of melatonin therapy in DMD patients.
OBJECTIVES: To analyze whether the antioxidant melatonin could reduce the hyperoxidative status in the blood of patients with Duchenne's muscular dystrophy. DESIGN AND METHODS: Ten patients aged 12.8±0.9 years were treated with melatonin (60mg at 21:00h plus 10mg at 09:00h) for 9 months, and erythrocyte markers of oxidative stress were determined at 3, 6, and 9 months of treatment. Healthy age- and sex-matched subjects served as controls. RESULTS: Prior to treatment, the patients had higher glutathione disulfide/glutathione ratio and higher glutathione transferase and superoxide dismutase activities, and lower glutathione reductase activity than controls. After 3 months of melatonin treatment, the hyperoxidative status of these patients was counteracted, being reduced to the normal redox state between 3 and 9 months. CONCLUSION: These results, together with the reduction in the inflammatory process and in muscle injury recently reported in the same patients, support the efficacy of melatonin therapy in DMDpatients.
Authors: Mariam Chahbouni; María Del Señor López; Antonio Molina-Carballo; Tomás de Haro; Antonio Muñoz-Hoyos; Marisol Fernández-Ortiz; Ana Guerra-Librero; Darío Acuña-Castroviejo Journal: Molecules Date: 2017-10-14 Impact factor: 4.411
Authors: Jennifer E Hewitt; Amelia K Pollard; Leila Lesanpezeshki; Colleen S Deane; Christopher J Gaffney; Timothy Etheridge; Nathaniel J Szewczyk; Siva A Vanapalli Journal: Dis Model Mech Date: 2018-12-04 Impact factor: 5.758
Authors: Tahnee L Kennedy; Lee Moir; Sarah Hemming; Ben Edwards; Sarah Squire; Kay Davies; Simon Guiraud Journal: Skelet Muscle Date: 2017-10-24 Impact factor: 4.912